Evidence map›Paper›PMID 39847442›Full record

ArticleJCI insight2025

Aging and inflammation limit the induction of SARS-CoV-2-specific CD8+ T cell responses in severe COVID-19.

Gaëlle Autaa, Laura Papagno, Takuto Nogimori, Andrea Boizard-Moracchini, Daniil Korenkov, Maeva Roy, Koichiro Suzuki, Yuji Masuta, Eoghann White, Sian Llewellyn-Lacey and 7 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  2. The ageing immune system and its battle with viruses.The Journal of general virology · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Gaëlle AutaaUniversity of Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000 Bordeaux, France.
Laura PapagnoUniversity of Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000 Bordeaux, France.
Takuto NogimoriLaboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Andrea Boizard-MoracchiniCHU Bordeaux, Laboratory of Immunology and Immunogenetics, 33000 Bordeaux, France.
Daniil KorenkovUniversity of Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000 Bordeaux, France.
Maeva RoyCHU Bordeaux, Laboratory of Immunology and Immunogenetics, 33000 Bordeaux, France.
Koichiro SuzukiThe Research Foundation for Microbial Diseases of Osaka University (BIKEN), Osaka, Japan.
Yuji MasutaLaboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Eoghann WhiteUniversity of Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000 Bordeaux, France.
Sian Llewellyn-LaceyDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
Yasuo YoshiokaThe Research Foundation for Microbial Diseases of Osaka University (BIKEN), Osaka, Japan.
Francesco NicoliDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
David A PriceDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
Julie Dechanet-MervilleUniversity of Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000 Bordeaux, France.
Takuya YamamotoLaboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Isabelle PellegrinUniversity of Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000 Bordeaux, France.
Victor AppayUniversity of Bordeaux, CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, 33000 Bordeaux, France.

Funding

Wellcome Trust
6 · The paper itself

Abstract

CD8+ T cells are critical for immune protection against severe COVID-19 during acute infection with SARS-CoV-2. However, the induction of antiviral CD8+ T cell responses varies substantially among infected people, and a better understanding of the mechanisms that underlie such immune heterogeneity is required for pandemic preparedness and risk stratification. In this study, we analyzed SARS-CoV-2-specific CD4+ and CD8+ T cell responses in relation to age, clinical status, and inflammation among patients infected primarily during the initial wave of the pandemic in France or Japan. We found that age-related contraction of the naive lymphocyte pool and systemic inflammation were associated with suboptimal SARS-CoV-2-specific CD4+ and, even more evidently, CD8+ T cell immunity in patients with acute COVID-19. No such differences were observed for humoral immune responses targeting the spike protein of SARS-CoV-2. We also found that the proinflammatory cytokine IL-18, concentrations of which were significantly elevated among patients with severe disease, suppressed the de novo induction and memory recall of antigen-specific CD8+ T cells, including those directed against SARS-CoV-2. These results potentially explain the vulnerability of older adults to infections that elicit a profound inflammatory response, exemplified by acute COVID-19.

Indexed as

AgingCD8-Positive T-LymphocytesCOVID-19InflammationSARS-CoV-2AdultAgedAged, 80 and overCD4-Positive T-LymphocytesFemaleFranceHumansInterleukin-18JapanMaleMiddle AgedInterleukin-18AgingCellular immune responseCOVID-19ImmunologyT cells

Identifiers

PMID39847442
PMCPMC11949069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.